Skip to main content

Research Repository

Advanced Search

Procalcitonin Evaluation of Antibiotic Use in COVID-19 Hospitalised Patients (PEACH): Protocol for a Retrospective Observational Study

Euden, Joanne; Pallmann, Philip; Grozeva, Detelina; Albur, Mahableshwar; Bond, Stuart E.; Brookes-Howell, Lucy; Dark, Paul; Hellyer, Thomas; Hopkins, Susan; Howard, Philip; Llewelyn, Martin J.; Maboshe, Wakunyambo; McCullagh, Iain J.; Ogden, Margaret; Parsons, Helena; Partridge, David; Powell, Neil; Shaw, Dominick; Shinkins, Bethany; Szakmany, Tamas; Todd, Stacy; Thomas-Jones, Emma; West, Robert M.; Carrol, Enitan D.; Sandoe, Jonathan A. T.; PEACH Study Group

Procalcitonin Evaluation of Antibiotic Use in COVID-19 Hospitalised Patients (PEACH): Protocol for a Retrospective Observational Study Thumbnail


Authors

Joanne Euden

Philip Pallmann

Detelina Grozeva

Mahableshwar Albur

Stuart E. Bond

Lucy Brookes-Howell

Paul Dark

Thomas Hellyer

Susan Hopkins

Philip Howard

Martin J. Llewelyn

Wakunyambo Maboshe

Iain J. McCullagh

Margaret Ogden

Helena Parsons

David Partridge

Neil Powell

Dominick Shaw

Bethany Shinkins

Tamas Szakmany

Stacy Todd

Emma Thomas-Jones

Robert M. West

Enitan D. Carrol

Jonathan A. T. Sandoe

PEACH Study Group



Contributors

Fernando Albericio
Editor

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel virus responsible for the coronavirus disease 2019 (COVID-19) pandemic. Although COVID-19 is a viral illness, many patients admitted to hospital are prescribed antibiotics, based on concerns that COVID-19 patients may experience secondary bacterial infections, and the assumption that they may respond well to antibiotic therapy. This has led to an increase in antibiotic use for some hospitalised patients at a time when accumulating antibiotic resistance is a major global threat to health. Procalcitonin (PCT) is an inflammatory marker measured in blood samples and widely recommended to help diagnose bacterial infections and guide antibiotic treatment. The PEACH study will compare patient outcomes from English and Welsh hospitals that used PCT testing during the first wave of the COVID-19 pandemic with those from hospitals not using PCT. It will help to determine whether, and how, PCT testing should be used in the NHS in future waves of COVID-19 to protect patients from antibiotic overuse. PEACH is a retrospective observational cohort study using patient-level clinical data from acute hospital Trusts and Health Boards in England and Wales. The primary objective is to measure the difference in antibiotic use between COVID-19 patients who did or did not have PCT testing at the time of diagnosis. Secondary objectives include measuring differences in length of stay, mortality, intensive care unit admission, and resistant bacterial infections between these groups.

Citation

Euden, J., Pallmann, P., Grozeva, D., Albur, M., Bond, S. E., Brookes-Howell, L., …PEACH Study Group. (2022). Procalcitonin Evaluation of Antibiotic Use in COVID-19 Hospitalised Patients (PEACH): Protocol for a Retrospective Observational Study. Methods and Protocols, 5(6), Article 95. https://doi.org/10.3390/mps5060095

Journal Article Type Article
Acceptance Date Nov 24, 2022
Online Publication Date Nov 28, 2022
Publication Date Dec 1, 2022
Deposit Date Dec 5, 2022
Publicly Available Date Mar 29, 2024
Journal Methods and Protocols
Electronic ISSN 2409-9279
Publisher MDPI AG
Peer Reviewed Peer Reviewed
Volume 5
Issue 6
Article Number 95
DOI https://doi.org/10.3390/mps5060095
Keywords Biochemistry, Genetics and Molecular Biology (miscellaneous); Structural Biology; Biotechnology
Public URL https://nottingham-repository.worktribe.com/output/14322514
Publisher URL https://www.mdpi.com/2409-9279/5/6/95
Additional Information Authors on behalf of the PEACH Study Group

Files




You might also like



Downloadable Citations